- Advertisement -


Monday, 21 September 2020


‘Complicated, costly and slow’ dementia trials are delaying future treatments, Alzheimer’s Research UK warns

- Advertisement -

ALZHEIMER’S Research UK has called on the government to use the investment promised for a ‘Dementia Moonshot’ to transform the way the UK carries out clinical trials for dementia, in an effort to find life-changing treatments sooner.

new report, from the Schaeffer Center for Health Policy & Economics and Gates Ventures, has found that current trials are ‘more complicated, costly and slower’ when compared to other health areas. The study found seven key barriers to clinical trials for Alzheimer’s disease, which included lack of awareness from those affected, fear of a diagnosis, unclear disease diagnoses as well as a lack of diagnostics and limited treatments.

The report found that around 99% of eligible individuals are never referred to or consider participating in an Alzheimer’s clinical trial. And while there are nearly one million people in the UK living with dementia, there are currently no treatments to slow, stop or prevent the diseases, most commonly Alzheimer’s, that cause it.

During the 2019 election, the Conservative Manifesto promised to double funding for dementia research to over £160 million a year, as part of a ‘Dementia Moonshot’ programme to find a cure for the condition and speed up clinical trials for new treatments. The UK’s leading dementia research charity is now urging the government to allocate funding in the upcoming comprehensive spending review to improve dementia clinical trials,  making the UK a go-to place to carry out trials and speed up progress towards new treatments.

Samantha Benham-Hermetz, Director of Policy and Public Affairs at Alzheimer’s Research UK, said:

“While we have seen a boost in investment for dementia research over the last decade, and progress is being made in the lab, this report highlights trials for promising dementia treatments can be complicated, costly and slow. But as we’ve seen in recent months with COVID-19, breakthrough research into life-threatening conditions can happen at pace, and collaboration and innovation can speed up trials. We need to mirror this approach to make breakthroughs in dementia research.

“To bring about life-changing treatments sooner, we need targeted government investment to make the UK the go-to place for clinical research. That’s why we’re urging the government to deliver on its Dementia Moonshot promise to double the dementia research budget and, as part of this investment, to establish a high performing network of clinical trial sites. In doing so, more people affected by dementia will be able to participate in clinical trials, more trials will be completed successfully and this will speed up progress towards innovative new treatments. Overcoming the barriers to clinical trials we face today will enable us to make the biggest difference in the lives of people affected by dementia in the future.

“With almost one million people in the UK today living with dementia, yet no new treatments for the condition in almost 20 years, we don’t have a moment to waste.”

- Advertisement -
- Advertisement -

Stay Connected


Must Read

Revolutionary piece of equipment will support surgeons operating during pandemic

LEEDS Cares funds revolutionary piece of equipment to help support surgeons operating during the pandemic. Leeds Cares has announced that Leeds Teaching Hospitals is now...

New report: How to tackle climate change through community action

THE National Lottery Community Fund has today published a new report sharing learning and insights from recent environmental projects made possible thanks to National...
- Advertisement -

Employment News

Samaritans appoints Keith Leslie as new Chair of Trustees

THE leading suicide prevention charity in the UK and ROI has appointed Keith Leslie as the new Chair of Trustees at Samaritans. Keith joins Samaritans...

The Big Issue makes two new appointments

THE Big Issue is expanding its reporting team with the appointment of a new Digital Editor and the newly created role of Digital Producer. Alastair...

New asbestos-related cancer nurse specialist appointed for South Tyneside and Sunderland

JOANNE Anderson has been appointed as a new Mesothelioma UK Clinical Nurse Specialist at South Tyneside and Sunderland NHS Foundation Trust. Joanne will be...

Related News

Cardiff dementia researchers supported by South Wales Freemasons

RESEARCH into a crucial protein linked to the development of Alzheimer's has been supported by a £76,000 grant from South Wales Freemasons. The grant is...

£25m fund to support the Arts announced by the Garfield Weston Foundation

THE Weston family are launching a new £25m fund to support the cultural sector as it attempts to recover following the impact of COVID-19....

The Burdett Trust for Nursing awards grant to Mesothelioma UK

INDEPENDENT charitable trust, The Burdett Trust for Nursing is donating a £10,000 grant to Mesothelioma UK, the national asbestos-related cancer charity. The funding will...

“MS turned my ‘perfect life’ into a living nightmare,” says gold-medalist Stephanie Millward MBE

PARALYMPIC gold medallist Stephanie Millward MBE will be swimming 100 kilometres to raise funds for the MS Society. The 39-year-old, who has multiple sclerosis (MS),...

End of an era for Cheshire Charity Chief

LEADING Cheshire Charity Active Cheshire has formally announced the departure of their long-serving CEO, Anne Boyd. Anne has led the Charity for 8 years, transforming,...
- Advertisement -